Rationale, design, and methodology of the EPIC (Epidemiology of Polypharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients) study

Basit Öğe Kaydı
dc.authoridozdemir, ibrahim halil/0000-0003-3953-4387
dc.contributor.authorOzlek, Eda
dc.contributor.authorCekic, Edip Guvenc
dc.contributor.authorOzlek, Bulent
dc.contributor.authorCil, Cem
dc.contributor.authorCelik, Oguzhan
dc.contributor.authorDogan, Volkan
dc.contributor.authorBasaran, Ozcan
dc.date.accessioned2025-01-21T16:43:56Z
dc.date.available2025-01-21T16:43:56Z
dc.date.issued2019
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjective: The aim of this study is to assess the prevalence of polypharmacy, inappropriate drug use, and drug-drug interactions (DDIs) in elderly patients presenting at outpatient cardiology clinics in Turkey. Methods: The EPIC (Epidemiology of Polypharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients) study will be an observational, real-world, multicenter study conducted to evaluate DDIs and polypharmacy in elderly cardiac outpatients. All consecutive patients (aged >= 65 years) admitted to outpatient cardiology clinics between July 30, 2018 and July 30, 2019 who provide written, informed consent will be enrolled. A total of approximately 5000 patients are to be enrolled in this non-interventional study. All of the data will be collected at one point in time and current clinical practice will be evaluated (ClinicalTrials.gov NCT03370523). Result: Patient demographics, comorbid disease characteristics, laboratory test results, and details of medication use will be collected using self-reports and medical records. The severity of comorbid disease will be recorded and scored according to Charlson Comorbidity Index (CCI) and patients will be divided into 3 groups: mild, those with a CCI score of 1-2; moderate, those with a CCI score of 3-4; and severe, those with a CCI score of >= 5. Polypharmacy will be defined as the use of 5 or more medications at one time. DDIs will be determined using the Lexicomp Online drug interaction screening tool and potentially inappropriate medications will be defined based on the 2015 update of the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Severe drug interactions will be defined as those in category D or X. Conclusion: EPIC will be the first large-scale study in Turkey to evaluate polypharmacy, potentially inappropriate medications, and DDIs in elderly cardiac outpatients in a real-world clinical setting.
dc.identifier.doi10.5543/tkda.2019.27724
dc.identifier.endpage398
dc.identifier.issn1016-5169
dc.identifier.issue5
dc.identifier.pmid31311898
dc.identifier.startpage391
dc.identifier.urihttps://doi.org/10.5543/tkda.2019.27724
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25362
dc.identifier.volume47
dc.identifier.wosWOS:000475438700008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi-Archives of The Turkish Society of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectCardiac outpatients; drug-drug interactions; elderly; polypharmacy
dc.titleRationale, design, and methodology of the EPIC (Epidemiology of Polypharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients) study
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu